Efficacy and safety of vedolizumab in elderly patients with inflammatory bowel disease: a matched case-control study

Clicks: 124
ID: 270175
2019
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Star

Ranked #2 of 2 articles by views in Gastroenterology report

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
In a real-world setting, vedolizumab was demonstrated to have an efficacy and safety profile among elderly IBD patients that were comparable to younger controls.
Reference Key
p2019gastroenterologyefficacy Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Shashi P;Gopalakrishnan D;Parikh MP;Shen B;Kochhar G;;
Journal Gastroenterology report
Year 2019
DOI
DOI not found
URL
https://www.pubmed.gov/32843978/
Keywords
National Center for Biotechnology Information NCBI NLM MEDLINE pubmed abstract nih national institutes of health national library of medicine pmid:32843978 pmc7434586 doi:10.1093/gastro/goz041 preeti shashi dharmesh gopalakrishnan gursimran kochhar

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.